<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="999">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148143</url>
  </required_header>
  <id_info>
    <org_study_id>RALOX 202102</org_study_id>
    <nct_id>NCT05148143</nct_id>
  </id_info>
  <brief_title>RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor</brief_title>
  <acronym>RALOXBTC</acronym>
  <official_title>Raltitrexed Combined With Oxaplatin as Second Line Treatment for Advanced Malignant Biliary System Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to explore the safety and efficacy of raltitrexed combined with&#xD;
      oxaplatin as second line treatment for advanced malignant biliary system tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to explore the safety and efficacy of raltitrexed combined with&#xD;
      oxaplatin as second line treatment for advanced malignant biliary system tumor. Single&#xD;
      arm，phase II study for patients with cholangiocarcinoma or gallbladder carcinoma after first&#xD;
      line treatment failure to explore effection and safety of raltitrexed combined with oxaplatin&#xD;
      as second line treatment；Sample size：50.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS（Progression Free Survival）</measure>
    <time_frame>24 months</time_frame>
    <description>PFS is defined as the time interval from initiation of treatment to the first date of documented tumor progression or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>24 months</time_frame>
    <description>Overall Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>36 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>24 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qol ( quality of life )</measure>
    <time_frame>24 months</time_frame>
    <description>EORTC-QLQ-C30 is a cancer-specific instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse Event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cholangioadenoma</condition>
  <arm_group>
    <arm_group_label>RALOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltitrexed combined with oxaplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed combined with oxaplatin</intervention_name>
    <description>Raltitrexed combined with oxaplatin as second line treatment of cholangiocarcinoma</description>
    <arm_group_label>RALOX</arm_group_label>
    <other_name>Sai Wei Jian</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. 18-75 years old.&#xD;
&#xD;
          2. Patients with unresectable advanced advanced Gallbladder carcinoma or&#xD;
             Cholangiocarcinoma confirmed by histology or cytology.&#xD;
&#xD;
          3. First-line chemotherapy failure (toxic side effects can not be tolerated, disease&#xD;
             progression during treatment or relapse after treatment) ;Or the disease recurred&#xD;
             within 6 months after completion of adjuvant chemotherapy.&#xD;
&#xD;
          4. At least one measurable lesion according to RECIST1.1 criteria.&#xD;
&#xD;
          5. ECOG: 0 ~ 1.&#xD;
&#xD;
          6. Life expectancy ≥ 12 Weeks.&#xD;
&#xD;
          7. The major organs were functioning normally, and the laboratory examination results&#xD;
             within 1 week met the following conditions before enrollment:①Absolute neutrophil&#xD;
             count (ANC)≥1.5×109/L ②Platelet count（PLT）≥80.0 × 109/L ③Hemoglobin concentration（HB）&#xD;
             ≥90g/L④ Total bilirubin（TB）≤1.5×ULN ⑤ Serum creatinine （Cr）≤l.5×ULN ，Endogenous&#xD;
             creatinine clearance &gt;60ml/min（Cockcroft-Gault Formula ）⑥Aspartate aminotransferase&#xD;
             (AST), Alanine aminotransferase (ALT), Alkaline phosphatase(AP): ≤3 ×ULN (≤5 ×ULN for&#xD;
             metastases to liver).&#xD;
&#xD;
          8. Sign the informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Allergic to any research drug and its excipients.&#xD;
&#xD;
          2. Prior use of raltitrexed or oxaliplatin.&#xD;
&#xD;
          3. History of other malignancies, except cured Basal cell or squamous Cell Carcinoma of&#xD;
             the skin and carcinoma in situ of the cervix.&#xD;
&#xD;
          4. There is a history of brain metastases.&#xD;
&#xD;
          5. History of psychotropic drug abuse and cannot quit or has a mental disorder.&#xD;
&#xD;
          6. Uncontrolled chronic infectious and non-infectious diseases.&#xD;
&#xD;
          7. Active or clinically poorly controlled severe infection&#xD;
&#xD;
          8. Other conditions that the researchers think should be ruled out.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Yuan, Ph.D&amp;MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Yuan, Ph.D&amp;MD</last_name>
    <phone>13858193601</phone>
    <email>yuanying1999@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Second Affiliated Hospital of Medical College of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Yuan</last_name>
      <phone>13858193601</phone>
      <email>yuanying1999@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ying Yuan, Ph.D &amp; MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cholangioadenoma</keyword>
  <keyword>first line treatment failure</keyword>
  <keyword>raltitrexed;</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma, Bile Duct</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

